Xencor (NASDAQ:XNCR) Sets New 1-Year Low – Here’s Why

Shares of Xencor, Inc. (NASDAQ:XNCR) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $13.91 and last traded at $14.12, with a volume of 23914 shares trading hands. The stock had previously closed at $14.46.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company cut their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday. JPMorgan Chase & Co. lifted their price target on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Stock Performance

The firm’s 50-day moving average price is $19.23 and its 200 day moving average price is $20.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $976.67 million, a price-to-earnings ratio of -4.39 and a beta of 0.70.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. On average, sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Buying and Selling

In related news, Director Alan Bruce Montgomery sold 1,421 shares of Xencor stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total transaction of $38,409.63. Following the transaction, the director now owns 9,140 shares of the company’s stock, valued at $247,054.20. This trade represents a 13.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.23% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of XNCR. GAMMA Investing LLC lifted its position in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV lifted its position in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its position in shares of Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 949 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,040 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in shares of Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 1,282 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.